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Hypoxia is a physiological or pathological condition of a deficiency of oxygen supply in the body as a whole or
within a tissue. During hypoxia, tissues undergo a series of physiological responses to defend themselves against a
low oxygen supply, including increased angiogenesis, erythropoiesis, and glucose uptake. The effects of hypoxia are
mainly mediated by hypoxia-inducible factor 1 (HIF-1), which is a heterodimeric transcription factor consisting of α
and β subunits. HIF-1β is constantly expressed, whereas HIF-1α is degraded under normal oxygen conditions.
Hypoxia stabilizes HIF-1α and the HIF complex, and HIF then translocates into the nucleus to initiate the expression
of target genes. Hypoxia has been extensively studied for its role in promoting tumor progression, and emerging
evidence also indicates that hypoxia may play important roles in physiological processes, including mammary
development and lactation. The mammary gland exhibits an increasing metabolic rate from pregnancy to lactation
to support mammary growth, lactogenesis, and lactation. This process requires increasing amounts of oxygen
consumption and results in localized chronic hypoxia as confirmed by the binding of the hypoxia marker pimonidazole
HCl in mouse mammary gland. We hypothesized that this hypoxic condition promotes mammary development and
lactation, a hypothesis that is supported by the following several lines of evidence: i) Mice with an HIF-1α deletion
selective for the mammary gland have impaired mammary differentiation and lipid secretion, resulting in lactation
failure and striking changes in milk compositions; ii) We recently observed that hypoxia significantly induces HIF-1α-
dependent glucose uptake and GLUT1 expression in mammary epithelial cells, which may be responsible for the
dramatic increases in glucose uptake and GLUT1 expression in the mammary gland during the transition period from
late pregnancy to early lactation; and iii) Hypoxia and HIF-1α increase the phosphorylation of signal transducers and
activators of transcription 5a (STAT5a) in mammary epithelial cells, whereas STAT5 phosphorylation plays important
roles in the regulation of milk protein gene expression and mammary development. Based on these observations,
hypoxia effects emerge as a new frontier for studying the regulation of mammary development and lactation.
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Oxygen is critical for cellular aerobic metabolism in many
higher organisms, including mammals, as it is the final
electron acceptor in the electron transport chain of oxida-
tive phosphorylation in mitochondria (Figure 1). Aerobic
metabolism is 19 times more efficient in energy produc-
tion than anaerobic metabolism: a molecule of glucose,
the major energy source in most mammalian cells, pro-
duces up to 38 molecules of ATP in aerobic metabolism
though only 2 in anaerobic metabolism [1]. In addition to
efficient energy production, aerobic metabolism produces* Correspondence: fzhao@uvm.edu
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stated.the end product H2O, whereas anaerobic metabolism
produces lactate, which is normally removed in the liver
with the requirement of oxygen in mammals. Therefore,
an oxygen supply and the maintenance of oxygen homeo-
stasis are essential in aerobic organisms.
Tissues in the body are exposed to different levels of
oxygen, which are affected by the oxygen supply and
tissue metabolic rate and range from near 159 mm Hg in
the upper airway [the O2 partial pressure in the atmos-
phere at sea level (pO2); 21% of atmospheric air] to as low
as 5 mm Hg (~1%) in the retina [2]. In most tissues, the
oxygen tension is between 10 and 45 mm Hg (3-6%) [3,4].
Hypoxia is a deficiency of oxygen supply in the entire
body (such as in high elevation exposure) or locally withinral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 Effects of hypoxia on glucose metabolism in cells. Glucose, taken up by facilitative glucose transporter 1 (GLUT1), is first phosphorylated
to glucose-6-phosphate by hexokinase (HK) and is then converted to pyruvate by glycolytic enzymes. Lactate dehydrogenase A (LDHA) converts
pyruvate to lactate when oxygen is limited. In well-oxygenated cells, pyruvate is actively taken up by the mitochondria and converted to acetyl
coenzyme A (CoA) by pyruvate dehydrogenase complex (PDC), which can be inactivated via phosphorylation by pyruvate dehydrogenase kinase 1
(PDK1). Acetyl-CoA enters the tricarboxylic acid cycle (TCA) to produce NADH, which is used to produce ATP through the electron transport chain
(ETC) via the transfer of electrons to oxygen to form water. The major enzymes affected by hypoxia are indicated. “+” = stimulation.
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due to different causes (such as tissue injury). The precise
hypoxic pO2 is different between organs, but a venous
pO2 of below 6% O2 can induce a hypoxic response in
most tissues, and 0.5-1% induces the maximal effects [5].
The body and its tissues have specific mechanisms to
sense oxygen levels and make the necessary adaptations
for survival under hypoxic conditions. Global oxygen is
sensed by central chemoreceptors located on ventro-
lateral surface of the medulla oblongata and peripheral
chemoreceptors in the aortic and carotid bodies [6-8].
These chemoreceptors control the respiration and heart
rates to adjust the oxygen supply in the entire body. In
localized hypoxia and chronic hypoxia, the tissues and
cells can also sense decreases in oxygen tension through
transcription factor complexes known as hypoxia-inducible
factors (HIFs) to restore homeostasis [2,9].
Cellular hypoxia signaling and HIFs
The effects of hypoxia in many tissues and cells are pri-
marily mediated by HIF-1 [10]. HIF-1 is a heterodimer
protein consisting of an HIF-1α subunit and an HIF-1β
subunit (Figure 2). Both subunits are similar in structure
and contain an N-terminal basic helix-loop-helix (bHLH)
domain, a Per-ARNT-Sim (PAS) domain, and a C-termi-
nal domain [11]. The PAS domain facilitates the heterodi-
merization of HIF-1α and HIF-1β [12], the bHLH domain
mediates the binding of HIF-1 to the consensus hypoxiaresponse element (HRE) 5′-RCGTG-3′(R = A or G) in tar-
get gene promoters or enhancers [9], and the C-terminus
of the proteins contains a transactivation domain and re-
cruits transcriptional co-factors. HIF-1β is constitutively
expressed in cells, whereas HIF-1α is under tight regula-
tion by oxygen levels [13]. Under normoxic conditions,
specific proline residues of HIF-1α are hydroxylated by
prolyl hydroxylase domain proteins (PHDs) [14] (Figure 2),
and hydoxylated HIF-1α is bound by the Von Hippel-
Lindau (vHL) protein, a component of the E3 ubiquitin
ligase complex, leading to HIF-1α ubiquitination and sub-
sequent proteasomal degradation [15-17] (Figure 2). Thus,
the transcriptional activity of HIF-1 is primarily deter-
mined by the cellular level of HIF-1α protein.
In addition to HIF-1α degradation, normoxia also
regulates the transcriptional activity of HIF-1α, where a
C-terminal asparagine in the transactivation domain of
HIF-1α is hydroxylated by factor inhibiting HIF-1 (FIH).
This hydroxylation of HIF-1α blocks its interaction with
the transcriptional coactivator p300 and CREB binding
protein (CBP) [18,19], thus disrupting the proper assem-
bly if HIF-1 at the HRE.
Cells sense oxygen availability through PHDs and FIH,
both of which are 2-oxoglutarate-dependent dioxy-
genases that require oxygen as a substrate. One oxygen
atom is used to hydroxylate a proline or asparagine of
HIF-1α, and the other oxygen atom is added to the co-
substrate α-ketoglutarate, converting it to carbon dioxide
Figure 2 The HIF-1α protein is stabilized under hypoxia and translocates to the nucleus to activate gene transcription. Two proline
residues of HIF-1α are hydroxylated by prolyl hydroxylase under normoxia. Hydroxylated HIF-1α is bound by the Von Hippel-Lindau (vHL) protein,
leading to its ubiquitination and subsequent degradation by the proteasome. In addition, a C-terminal asparagine in the transactivation domain
of HIF-1α is hydroxylated by factor inhibiting HIF-1 (FIH) under normoxia. The hydroxylation of HIF-1α blocks its interaction with the transcriptional
coactivator p300 and CREB binding protein (CBP), thereby disrupting the proper assembly of HIF-1 at the hypoxia response element (HRE) of its
target genes. Without oxygen, the proline and asparagine residues of HIF-1α cannot be hydroxylated; therefore, HIF-1α protein is stabilized,
translocates to the nucleus, forms a heterodimer with HIF-β and activates target gene transcription.
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tions, the activities of PHDs and FIH are repressed, and
HIF-1α is stabilized and able to translocate to the nucleus,
heterodimerize with HIF-1β, and activates target gene
transcription.
In addition to being regulated by oxygen stress, HIF-
1α has been shown to be regulated by other stimuli,
including nitric oxide, reactive oxygen species, nutrient
stress, and glycolytic intermediates (e.g., pyruvate and
lactate) [10,21-23]. Indeed, glycolytic intermediates may
act as competitors of the PHD substrate 2-oxoglutarate,
preventing PHD hydroxylation of HIF-1α.
HIF isoforms in addition to HIF-1α and HIF-1β have
been identified [2,24]. There are currently three structur-
ally related HIF-α isoforms that share a similar functional
mechanism [2]. In contrast to the ubiquitous expression
of HIF-1α, the expression of HIF-2α is commonly found
in tissues involved in oxygen delivery, such as endothelial
cells and cardiac myocytes [25]. The various isoforms may
also have selective transcriptional targets [2]. Additionally,
HIF-3α lacks the transactivation domain and thus may
play a dominant-negative role [26]. HIF-1α deletion in
mice is embryonic lethal, with cardiac and vascular defects
and decreased erythropoiesis [27-29]; in contrast, HIF-2α
deletion is either embryonic lethal, or death occurs shortly
after birth due to respiratory failure or mitochondrial
dysfunction [30].
Physiological responses of tissues to hypoxia
All nucleated cells have the ability of physiological alter-
ations to adapt to transient or chronic hypoxia. These
changes include enhancing glucose uptake, metabolic
switching from oxidative phosphorylation to anaerobicglycolysis to reduce oxygen consumption, and increa-
sing oxygen delivery by promoting angiogenesis and
erythropoiesis.
Glucose uptake
Glucose utilization in most mammalian cells is controlled
by its uptake. Glucose transport across the plasma mem-
brane of most mammalian cells is mediated by a family of
facilitative glucose transporters (GLUTs), which includes
14 structurally related members designated GLUT1-12,
GLUT14, and HMIT (H+/myo-inositol co-transporter)
[31]. Each transporter has a tissue-specific distribution
and distinct kinetic properties and exhibits differential
regulation by ambient glucose, oxygen levels, and hor-
mones [31]. Glucose transport is stimulated by hypoxia in
many cell types, and this response is largely mediated by
enhancing GLUT1 and GLUT3 transcription through
HIF-1α activation [32-34]. An HRE identified in an enhan-
cer region located approximately 2.7 kb upstream of the
transcription start site in mouse and rat GLUT1 genes is
reported to convey the response to hypoxia [35,36].
In addition to the direct regulation of GLUT transcrip-
tion by HIF-1α, hypoxia may also stimulate glucose uptake
by secondary mechanisms, such as by inhibiting oxidative
phosphorylation in mitochondria. The exposure to hyp-
oxia results in the inhibition of oxidative phosphorylation,
which, without the reduction of oxygen tension, in turn
stabilizes GLUT1 mRNA and up-regulates GLUT1 ex-
pression through enhancer elements that are independent
of HIF binding [35,36]. A serum-responsive element (SRE)
located approximately 100 nucleotides upstream of an
HRE in the mouse GLUT1 gene conveys the responses to
mitochondrial inhibitors [36]. In the rat GLUT1 gene, a
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start site responds to the inhibition of oxidative phos-
phorylation [35]. Furthermore, the induction of GLUT1
expression by low oxygen availability is rapid, whereas the
half-life of GLUT1 mRNA is not affected. In contrast, the
up-regulation of GLUT1 mRNA by the inhibition of
oxidative phosphorylation is a delayed response, and the
GLUT1 mRNA half-life increases significantly [35].
Metabolism
In aerobic metabolism, glucose is first converted to two
pyruvates through glycolysis in the cytoplasm; pyruvate
dehydrogenase complex (PDC) in the mitochondria then
catalyzes the conversion of pyruvate to acetyl-CoA, which
enters the tricarboxylic acid (TCA) cycle and produces
ATP via oxidative phosphorylation (Figure 1). However,
when the availability of O2 becomes limited, cells switch
from oxidative metabolism to anaerobic glycolysis by up-
regulating the expression of several key glycolytic genes,
including hexokinases 1 and 2 (HKs), lactate dehydro-
genase A (LDHA), and pyruvate dehydrogenase kinase 1
(PDK1) [2,4,13]. The up-regulation of glycolytic gene
expression is also mediated by HIF-1 via direct binding to
promoters or enhancers [37-40].
In addition to preventing substrates from entering oxi-
dative phosphorylation, hypoxia also regulates mitochon-
drial activity: it regulates cytochrome c oxidase (COX) by
switching isoform COX4-1 to COX4-2, which can use the
limited oxygen more efficiently [41]. Moreover, hypoxia
inhibits mitochondrial biogenesis by decreasing c-Myc
activity [42] and induces mitochondrial autophagy by up-
regulating BNIP3 [43].
Angiogenesis and erythropoiesis
Another strategy against hypoxia is to increase oxygen
delivery, which is performed in two ways. i) Hypoxia
induces angiogenesis, the growth of new blood vessels, to
deliver more oxygen and nutrients to hypoxic tissues, a
process that is primarily mediated via the up-regulation of
vascular endothelial growth factor (VEGF) expression by
HIF [44]. Hypoxia-induced angiogenesis plays important
roles in wound healing, inflammation, and pregnancy. ii)
In systemic hypoxia, genes related to red blood cell
production and oxygen transport are up-regulated [45].
Erythropoietin (EPO) was the first gene shown to be regu-
lated by hypoxia, and research on the underlying mechan-
ism led to the discovery of HIF [46,47]. HIF increases the
expression of EPO in the kidney and liver, stimulating the
production of red blood cells in the bone marrow.
Hypoxia also induces other proteins involved in iron
uptake and utilization to support the production of
hemoglobin [47].
In addition to the above changes, hypoxia can also
induce changes in gene expression to maintain a morealkaline intracellular pH to overcome the hostile acidic
extracellular environment resulted from lactate accumu-
lation [2].
Pathological implications of hypoxia in cancer and other
diseases
Many studies on the effects of hypoxia have been
conducted in cancer cells [48]. Indeed, hypoxia is a
characteristic feature of malignant solid cancers, such as
breast cancer. Cancer cells can grow and proliferate
without external growth signals and are insensitive to
growth suppressors and resistant to cell death [49].
Thus, highly aggressive and rapidly growing tumors are
exposed to hypoxia as a consequence of an inadequate
blood supply, which in turn plays a pivotal role in pro-
moting tumor progression and the resistance to therapy.
During tumor growth, hypoxia provides an array of
effects to favor tumor survival under the hypoxic condi-
tion. These effects include gene expression changes to
suppress apoptosis and support autophagy [50,51], geno-
type selection of cells with diminished apoptotic poten-
tial [52], increased GLUT expression and glucose uptake
[53], anabolic metabolism switching [54], and the loss of
genomic stability through the down-regulation of DNA
repair [55] and possibly increased reactive oxygen spe-
cies (ROS) production [56]. In addition, hypoxia can also
suppress immune responses [57] and enhance tumor
angiogenesis, vasculogenesis, the epithelial-mesenchymal
transition (EMT), invasiveness, and metastasis [2,58].
These effects may also play roles in the resistance to
cancer therapy [59]. Due to its multiple contributions to
tumor progression, hypoxia has been suggested to be a
negative prognostic factor for patient outcomes [60], and
many studies have shown that endogenous hypoxia
markers (e.g., HIF-1α, GLUT1, CA IX) are correlated
with poorer outcomes and more aggressive malignancies
[60,61]. Thus, it is not surprising that hypoxia has been
a high priority target for cancer therapy [59].
In addition to cancer, hypoxia is implicated in other
human diseases, such as ischemic heart disease (IHD),
stroke, kidney disease, chronic lung disease, and in-
flammatory disorders [62]. Furthermore, cellular hyp-
oxia may be a key factor in increasing glucose uptake by
adipocytes, contributing to adipose tissue dysfunction in
obesity [63,64].
Involvement of hypoxia in physiological processes
Studies have also demonstrated that HIF-1α is required
for embryonic development and the development and
growth of several murine tissues, implying a role for
hypoxia in these physiological processes. Most mam-
malian embryos develop at oxygen concentrations of
1% - 5%, thus hypoxia and HIF play important roles
in embryogenesis and placenta development by regulating
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null mice die by embryonic day (E) 10.5 due to an
impaired circulatory system [13]. HIF-1α deletion in the
cartilaginous growth plate of developing bone leads to
death of cells in the interior of the growth plate, indicating
that hypoxia plays an important role in chondrogenesis
[66]. Hypoxia promotes angiogenesis and osteogenesis in
bone by elevating the VEGF levels induced by HIF-1α in
osteoblasts, as HIF-1α overexpression results in extremely
dense, heavily vascularized long bones and a high level of
VEGF, whereas the lack of HIF-1α in osteoblasts leads to
significantly thinner and less vascularized long bones [67].
Hypoxia inhibits adipogenesis and the conditional knock-
out of HIF-1α in mouse embryonic fibroblasts impairs the
hypoxia-mediated inhibition of adipogenesis [68]. In
HIF-1α-deficient mice, hematopoietic stem cells (HSCs)
in bone marrow lose cell cycle quiescence, and HSC
numbers decrease [69]. B lymphocyte development is
abnormal in HIF-1α-deficient chimeric mice, inducing
autoimmunity [70].
Below, we introduce the emerging evidence of the
involvement of hypoxia in mammary development and
lactation.
Mammary development and lactation
The development of the mammary gland can be divided
into three stages, embryo, puberty, and pregnancy, and
the major development occurs during postnatal stages.
In mice, two milk lines form between the fore and hind
limbs of an E 10.5 embryo, and five pairs of placodes
arise along each of the two milk lines at E 11.5. The pla-
codes then invaginate into the underlying mesenchyme
to form small bulb-shaped buds. The mammary epithe-
lial cells of the buds proliferate from E 15.5 to form
sprouts that penetrate to the underlying fat pad and
form the rudimentary ductal tree and teats [71,72].
Canonical Wnt signaling plays an important role during
embryonic mammary development: Wnt 6, Wnt 10a,
and Wnt 10b are expressed during this period, and the
inhibition of Wnt signaling results in impaired placode
formation [72,73]. From birth to puberty, the mammary
gland first undergoes isometric growth (with the same
rate as the body), followed by allometric growth (2-4X
faster than body fat deposition). Robust duct branching
then begins at the onset of puberty. Terminal end buds
(TEBs) form from the tip of the rudimentary ductal tree
of the mouse mammary gland and drive pubertal
mammary development. TEBs are highly proliferative,
penetrating further into the fat pad, and the bifurcations
of TEBs form the primary ducts. TEBs continue to
invade into the fat pad until the primary ducts reach the
border of the fat pad, and the secondary ducts then
branch laterally from the primary ducts until the fat
pad is filled with extensive ducts [74]. In ruminants,the terminal ductal lobular units (TDLUs) are the
characteristic structures of postpubertal mammary
development. During this stage, estrogen and growth
hormone regulate duct branching, as the knock-out of
estrogen receptor (ER) α or growth hormone receptor
was found to impair duct development during puberty
[75,76]. During the early stage of pregnancy, short
tertiary side-branches form along the ductal system devel-
oped during puberty, a process that is regulated by pro-
gesterone, progesterone receptor, and downstream Wnt 4
signaling [77,78]. The mammary epithelial cells then pro-
liferate rapidly to form a lobuloalveolar structure within
the ductal branches. Prolactin is important for alveolar
morphogenesis, as the knock-out of prolactin receptor or
STAT5a, a major prolactin downstream-signaling mol-
ecule, results in lobuloalveolar defects [79,80]. During late
pregnancy, the mammary epithelial cells differentiate, and
lactogenesis occurs under the synergistic effects of prolac-
tin, glucocorticoids, and insulin [81]. Milk protein genes
and lipogenic genes are expressed, and lipid droplets form
in the epithelial cells. At the onset of lactation, the peak
blood levels of lactogenic hormones and withdrawal of
progesterone lead to copious milk secretion [81]. Exten-
sive angiogenesis to supply nutrients is associated with all
stages of mammary development [82]; in particular,
extensive capillaries form a basket-like architecture to
surround the alveoli during lobuloalveolar develop-
ment. The vascular density doubles from day 18 of
pregnancy to day 5 of lactation in mice [83]. In consistent
with vascular development, the expression of VEGF and
VEGF receptor in the rodent mammary gland increases
dramatically during pregnancy and lactation and decreases
during involution [84].
Oxygen uptake in the mammary gland during mammary
development and lactation
The mammary gland has high metabolic rates during
development and lactation and is thus considered to be
a benign, highly regulated tumor [85]. Although exten-
sive studies have been performed in the pathology of
hypoxia in breast cancer, limited attention has been
given to oxygen utilization in normal mammary develop-
ment and lactation, and reports on mammary oxygen
uptake have been largely limited to only a few early
studies [86-88]. The average O2 uptake of a lactating
mammary gland is 0.51-0.73 μmol/min/g in goats and
2.06 in rats [86-88]. Mammary O2 uptake is steadily
increased during late pregnancy and reaches the highest
levels in early lactation [89]. The O2 uptake in lactating
goats is twice that in the preparturient goat, and there is
a correlation between mammary O2 uptake and milk
secretion [87,88]. Starvation results in the virtual cessation
of milk production, with a 75% reduction in mammary oxy-
gen uptake [86], whereas growth hormone administration
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mice, the pO2 level in the mammary fat pad is, on average,
13.0 mm Hg (~2%), which is considerably lower than in
muscle (29.1 mm Hg, ~4%) [91]. However, a recent study
using phosphonated trityl probes in mice reported an
average mammary gland tissue pO2 of 52 mmHg [92],
which is consistent with the pO2 value reported in normal
breast tissue [93]. Nevertheless, it is likely that the mam-
mary gland develops chronic hypoxia during the rapid
mammary development in late pregnancy and in early
lactation because the oxygen consumption increases in
these periods to meet the increased metabolic rates.
To examine possible hypoxic conditions in the mam-
mary gland during mammary development, we recently
injected the hypoxia marker pimonidazole HCl into mice
from the virgin state to the early lactation state. Pimoni-
dazole HCl is a chemical that forms adducts with thiol
groups in proteins, peptides, and amino acids in hypoxic
cells (http://www.hypoxyprobe.com/), and these pimoni-
dazole adducts can be detected with specific antibodies.
Immunohistochemical staining of the mouse mammary
glands from different stages showed a hypoxic mammary
gland in all examined stages, but the staining was stronger
during late pregnancy and early lactation (Shao and Zhao,
unpublished preliminary observations), indicating a more
hypoxic condition in these stages.
Emerging evidence of a role of hypoxia in mammary
development and lactation
Consistent with the hypoxic condition in the mammary
gland during development and lactation, there is emerging
evidence that supports possible physiological roles of hyp-
oxia in these processes.
1) Selective deletion of HIF-1α in the mouse mammary
gland results in impaired mammary development and
lactation
The most compelling evidence of hypoxia’s role in
mammary development and lactation is from a targeted
gene-knockout study by Seagroves et al. (2003) [94].
Because the whole-genome knockout of the HIF-1α gene
is embryonic lethal, Seagroves et al. specifically removed
the HIF-1α gene from the mammary epithelial cells
(MECs) using mouse mammary tumor virus (MMTV)
promoter-directed cre-lox technology. No morphological
defects were observed in the HIF-1α-/- glands until day
15 of pregnancy when the mammary gland is well into
secretory differentiation. By day 15 of pregnancy, strik-
ing histological differences became obvious between the
wild-type and HIF-1α-/- glands. In particular, the HIF-
1α-/- glands had smaller alveoli with no protein or lipid
droplets due to impaired mammary differentiation. In
addition, the expression of milk proteins β-casein and α-
lactalbumin was decreased by over 50% in these glands.Surprisingly, the HIF-1α-/- glands showed no abnormal-
ity in microvessel pattering and vascular density, despite
the important role of hypoxia in angiogenesis [94]. How-
ever, this observation could be explained by HIF-1α only
being deleted in MECs and not in other cell types, such
as endothelial and stroma cells, and these cells could still
respond to the hypoxia conditions and retain intact
angiogenesis.
Furthermore, consistent alveolar defects and trapped
large lipid droplets were observed in the HIF-1α-/-
glands during lactation [94]. The glands weighed ~50%
of the wild-type glands at mid-lactation; additionally, the
HIF-1α-/- animals produced less milk than the wild-type
controls, and their milk was more viscous and contained
significantly elevated fat and ion contents.
These data clearly indicate that, although the ex-
pression of HIF-1α in MECs is not required for early
mammary development (mainly ductal morphogenesis),
it is essential for mammary secretory differentiation,
milk production, and lipid secretion, implying a role for
hypoxia in these physiological processes.
2) Hypoxia increases glucose uptake and GLUT1
expression in MECs
As in all mammalian cells, glucose is an important source
of energy and NADH and also serves as a substrate for
lipid, protein, and nucleotide syntheses in MECs. Glucose
is also the major and an essential precursor of lactose syn-
thesis in the lactating MECs. Mammary glucose uptake
increases gradually from late pregnancy and peaks at early
lactation [87,89], and mammary glucose transport activity
increases approximately 40-fold from the virgin state to
mid-lactation state in mice [95]. Glucose uptake in the
mammary gland is mediated by facilitative glucose trans-
porters (GLUTs) [31,96]. Mammary cells mainly express
GLUT1, GLUT8, and GLUT 12, with GLUT1 being the
predominant isoform [97], and there is a dramatic
increase in mammary GLUT expression from late preg-
nancy to early lactation [97], concomitantly with mam-
mary glucose uptake. We originally hypothesized that the
lactogenic hormones (prolactin, glucocorticoids, insulin,
and estrogen) are responsible for stimulating GLUT ex-
pression during lactogenesis. However, our recent study
challenged this hypothesis because these hormones failed
to stimulate GLUT expression in bovine mammary ex-
plants and primary MECs, even though they were able to
dramatically stimulate the expression of milk protein and
lipogenic genes [98].
We, thus, hypothesized that the mechanism underlying
the increase in GLUT expression in MECs during the
transition period from pregnancy to lactation involves
hypoxia signaling through hypoxia inducible factor-1α
(HIF-1α). To test this hypothesis, we recently studied the
effects of hypoxia on GLUT expression in bovine MECs.
Figure 3 Schematic diagram of proposed effects of hypoxia on
the mammary gland. Hypoxia stabilizes the hypoxia-inducible
factor-1α (HIF-1α), which stimulates: i) glucose uptake through
enhancing the expression of facilitative glucose transporter 1
(GLUT1), ii) angiogenesis through enhancing the expression of
vascular endothelial growth factor (VEGF), iii) anaerobic glycolysis
through up-regulating the expression of several key glycolytic genes,
including hexokinases 1 and 2 (HKs), lactate dehydrogenase A
(LDHA), and pyruvate dehydrogenase kinase 1 (PDK1), and iv)
mammary development, differentiation and lactation through
regulation of Notch, Wnt and STAT5 signaling pathways.
Shao and Zhao Journal of Animal Science and Biotechnology 2014, 5:9 Page 7 of 11
http://www.jasbsci.com/content/5/1/9Hypoxia (below 5% O2) significantly stimulated glucose
uptake and GLUT1 mRNA and protein expression in
bovine MECs yet decreased GLUT8 mRNA expression in
these cells (Shao and Zhao, unpublished observations). A
robust induction of HIF-1α protein was observed in the
bovine MECs, consistent with the observation in mouse
MECs [94]. Furthermore, an siRNA against HIF-1α com-
pletely abolished the up-regulation of GLUT1 by hypoxia
but had no effect on GLUT8 expression (Shao and Zhao,
unpublished observations).
Consistent with our study, the expression of GLUT1 in
mouse MECs is HIF-1α-dependent in a stage-dependent
manner in vivo. GLUT1 expression decreases by 60% in
HIF-1α-/- glands by day 16 of pregnancy, whereas no
difference was observed at mid-lactation [94]. In addition,
it has been shown that prolonged hypoxia stimulates
GLUT1 expression in bovine endothelial cells [99,100].
Taken together, the above evidence clearly show that
MECs and mammary endothelial cells are responsive to
hypoxia (as high as 5% O2) through HIF-1α.
3) Possible interactions of HIF-1α with other signaling
pathways in the mammary gland
The signal transducer and activator of transcription 5
(STAT5) is essential for mammary gland differentiation
and lactation [101,102] and is mainly activated by prolac-
tin and its receptor in the mammary gland. After binding
prolactin, the prolactin receptor phosphorylates and acti-
vates Janus kinase (JAK) 2. JAK2 then phosphorylates
STAT5, and STAT5 dimerizes and translocates to the
nucleus to stimulate target genes’ expression [103,104]. In
addition to the prolactin pathway, STAT5 can also be acti-
vated by epidermal growth factor (EGF), growth hormone,
insulin growth factor (IGF), estrogen, and progesterone
signaling pathways in the mammary gland [105]. STAT5
controls the population of luminal progenitor cells that
will differentiate to alveolar cells [106,107]. During lacto-
genesis and lactation, the prolactin-STAT5 pathway con-
trols the expression of milk protein genes and lipogenic
genes [81,108]. STAT5-null mice have impaired mammary
alveologenesis due to a reduction in the mammary lumi-
nal progenitor cell population and exhibit impaired milk
protein gene expression [109]. It has been reported that
hypoxia and HIF-1α can induce STAT5 phosphorylation
and enhance its DNA-binding activity in mammary
epithelial cells and breast cancer cells [110,111]. Thus,
hypoxia may be involved in mammary development and
lactation by regulating STAT5 activity.
Notch signaling responds to extrinsic or intrinsic devel-
opmental cues and regulates multiple cellular processes,
such as stem cell maintenance, cell fate specification, and
differentiation [112]. Upon ligand binding, the Notch pro-
tein is cleaved by presenilin/γ-secretase to release the
active intracellular domain (ICD), which translocates tothe nucleus to regulate the transcription of target genes
[113]. In the mammary gland, Notch represses mammary
stem cells expansion in the basal cell compartment [114]
and promotes luminal cell fate specification and prevents
myoepithelial cell lineage during pregnancy [114,115].
Hypoxia prevents differentiation in various stem and pre-
cursor cells, and research has shown that HIF-1α interacts
with the Notch ICD to activate Notch target genes, inhi-
biting the differentiation of myogenic and neutral precur-
sor cells [116]. In addition, FIH negatively regulates Notch
by hydroxylating two asparagine residues of ICD [117].
Therefore, hypoxia and Notch signaling may cross-talk to
regulate cell differentiation in the mammary gland.
Wnt proteins are involved in multiple events during em-
bryogenesis and adult tissue development, with effects on
cell fate specification, differentiation, mitogenic stimula-
tion, and stem cell self-renewal [118]. The Wnt signaling
pathways include the canonical pathway involving β-ca-
tenin and noncanonical pathways; the canonical pathway
has been investigated intensively and best characterized.
Wnt proteins bind to the cell surface receptor Frizzled in
conjunction with low-density lipoprotein receptor-related
proteins (LRPs), which transduce the signal to intra-
cellular proteins, leading to the stabilization of β-catenin.
β-Catenin then translocates to the nucleus and interacts
with transcription factor lymphoid enhancer-binding
factor 1/T cell-specific transcription factor (LEF/TCF) to
affect target gene transcription [118]. Wnt signaling is
essential for mammary rudiment formation in embryos, as
the lack of TCF or the overexpression of the Wnt
inhibitor Dkk-1 impairs the formation of mammary pla-
codes [73,119,120]. Wnt signals drive ductal branching
during pubertal mammary development, because the dele-
tion of LRP reduces duct branching and the overexpres-
sion of LRP increases duct branching in the virgin mouse
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factor downstream of progesterone signaling during preg-
nancy to stimulate lobular alveolar development [77,124].
During mammary development, both ductal and alveolar
epithelial cells originate from mammary stem cells, and
Wnt signaling serves as a rate-limiting self-renewal signal
to maintain mammary stem cells [125]. Most stem cells
reside in hypoxic niches, and research has shown that
Wnt signaling is modulated by hypoxia in embryonic stem
cells and neural stem cells by enhancing β-catenin activa-
tion and increasing LEF/TCF proteins [126]. Such interac-
tions may also exist in the mammary gland.
Conclusion
Increased oxygen and energy requirements, nutrient
stress, extensive angiogenesis, and metabolic switching to
glycolysis [127] in the mammary gland during the transi-
tion period from pregnancy to lactation make hypoxia a
possible regulator of these processes. The possible effects
of hypoxia on the mammary gland include, but not limit
to the stimulations of: i) glucose uptake through enhan-
cing the expression of GLUT1, ii) angiogenesis through
enhancing the expression of VEGF, iii) anaerobic glycolysis
through up-regulating the expression of several key glyco-
lytic genes, including HKs, LDHA, and PDK1, and iv)
mammary development, differentiation and lactation
through regulation of Notch, Wnt and STAT5 signaling
pathways (Figure 3).
However, based on above evidence, it is important to note
that, although HIF-1α is clearly required in normal mam-
mary development and lactation, there is a possibility that
hypoxia per se may not be the major or only stimulus of
HIF-1α activity in the mammary gland. As mentioned
above, in addition to being regulated by hypoxia, HIF-1α
stability has been shown to be regulated by other stimuli,
including nitric oxide, reactive oxygen species, nutrient
stress, and glycolytic intermediates [10,21-23]. Furthermore,
several studies have shown that hypoxia causes mammary
epithelial disorganization and induces a cancer cell-like
phenotype in human MECs [128-130]. Thus, to link an ef-
fect of hypoxia to mammary development and lactation, it
is essential to quantitatively measure oxygen tension
changes in the mammary gland from pregnancy to lacta-
tion. Our hypothesis is that a small degree of the hypoxic
condition is involved in mammary development and lacta-
tion from late pregnancy to early lactation, whereas more
severe hypoxia is involved in breast cancer development.
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